| Market Cap | 18.74M | P/E | - | EPS this Y | -134.30% | Ern Qtrly Grth | - |
| Income | -11.45M | Forward P/E | -6.15 | EPS next Y | 19.10% | 50D Avg Chg | -16.00% |
| Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | -19.00% |
| Dividend | N/A | Price/Book | 0.28 | EPS next 5Y | - | 52W High Chg | -58.00% |
| Recommedations | 2.00 | Quick Ratio | 7.62 | Shares Outstanding | 10.14M | 52W Low Chg | 24.00% |
| Insider Own | 38.39% | ROA | -11.62% | Shares Float | 4.65M | Beta | 1.52 |
| Inst Own | 21.23% | ROE | -18.56% | Shares Shorted/Prior | 3.86K/517 | Price | 2.52 |
| Gross Margin | - | Profit Margin | - | Avg. Volume | 26,259 | Target Price | 7.98 |
| Oper. Margin | - | Earnings Date | Nov 11 | Volume | 4,311 | Change | -2.33% |
Acasti Pharma Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal betamethasone spray for the treatment of ataxia-telangiectasia; and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia. The company was incorporated in 2002 and is headquartered in Princeton, New Jersey.
| Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Kavuru Vimal | Director Director | Sep 25 | Buy | 1.848 | 676,371 | 1,249,934 | 1,188,076 | 09/27/23 |